Erratum: Potential role for retinoic acid in patients with cushing's disease (Journal of Clinical Endocrinology and Metabolism (2012) 97 (3577-3583) DOI: 10.1210/jc.2012-2328);Potential role for retinoic acid in patients with Cushing's disease

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3577-3583

  Giraldi, Francesca Pecori ^a   Ambrogio, Alberto Giacinto ^a   Andrioli, Massimiliano ^a   Sanguin, Francesca ^c   Karamouzis, Iannis ^b   Corsello, Salvatore Maria ^d   Scaroni, Carla ^c   Arvat, Emanuela ^b   Pontercorvi, Alfredo ^d   Cavagnini, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCOSE; HYDROCORTISONE; RETINOIC ACID;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; LONG TERM CARE; MALE; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; XEROPHTHALMIA;

EID: 84867241291     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1321     Document Type: Erratum

References (35)

1. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M 2008 Treatment of ACTH-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454-2462 (Pubitemid 352008503)
2. Pecori Giraldi F, Cavagnini F 2008 Advances in the medical management of Cushing's syndrome. Expert Opin Pharmacother 9:2423-2433
3. Pecori Giraldi F, Scaroni C, Arvat E, De Martin M, Giordano R, Albiger N, Leao AAS, Picu A, Mantero F, Cavagnini F 2006 Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 64:219-224
4. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A 2009 The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223-230
5. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM 2012 A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 366:914-924
6. Páez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grübler Y, Missale C, Arzt E, Stalla GK 2001 Retinoic acid prevents experimental Cushing's syndrome. J Clin Invest 108:1123-1131 (Pubitemid 32995370)
7. Giacomini D, Páez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M, Renner U, Stalla GK, Arzt E 2006 Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147:247-256 (Pubitemid 43004278)
8. Castillo V, Giacomini D, Páez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E 2006 Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147:4438-4444 (Pubitemid 44268395)
9. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F 1999 Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84:440-448
10. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM 2008 Diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526-1540 (Pubitemid 351656485)
11. Hamilton M 1960 A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
12. Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Müller OA, Fahlbusch R 2008 Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108:9-18
13. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T 2008 Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 158:91-99 (Pubitemid 351211045)
14. Invitti C, De Martin M, Danesi L, Cavagnini F 1995 Effect of injectable bromocriptine in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 103:266-271
15. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462 (Pubitemid 38619889)
16. Heaney AP, Fernando M, Yong WH, Melmed S 2002 Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287 (Pubitemid 35373561)
17. Suri D, Weiss RE 2005 Effect of pioglitazone on ACTH and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 90:1340-1346 (Pubitemid 40463985)
18. DeHerder WW, Lamberts SW 1996 Is there a role for somatostatin-and its analogs in Cushing's syndrome? Metabolism 45(8 Suppl 1):83-85
19. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286: 69-74 (Pubitemid 351680237)
20. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured humancorticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654 (Pubitemid 40575811)
21. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488 (Pubitemid 44833427)
22. Pecori Giraldi F, Cassarino F, Pagliardini L, Asnaghi V, Cavagnini F 2011 The human POMC promoter: where do we stand? J Endocrinol Invest 34:454-460
23. Wu Q, Li Y, Liu R, Agadir A, Lee MO, Liu Y, Zhang X 1997 Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J 16:1656-1669 (Pubitemid 27151961)
24. Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein C, Xu Y, Wang L, Tsai SY, Tsai MJ, Xu HE 2008 Identification of COUP-TFII orphan nuclear receptor as a retinoic-acid activated receptor. PloS Biol 6:e227
25. Qureshi AC, Bahri A, Breen LA, Barnes SC, Powrie JK, Thomas SM 2007 The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) 66:632-635 (Pubitemid 46699528)
26. Kreutzer J, Jeske I, Hofmann B, Blumcke I, Fahlbusch R, Buchfelder M, Buslei R 2009 No effect of the PPAR-γ agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro an in vivo. Clin Neuropathol 28:430-439
27. Pecori Giraldi F, Pesce S, Maroni P, Pagliardini L, Lasio G, Losa M, Cavagnini F 2010 Inhibitory effect of preproTRH(178-199) on ACTH secretion by human corticotrope tumours. J Neuroendocrinol 22:294-300
28. Pecori Giraldi F, Pagliardini L, Cassarino MF, Losa M, Lasio G, Cavagnini F 2011 Responses to CRH and dexamethasone in a large series of human ACTH-secreting pituitary adenomas in vitro reveal manifold corticotroph tumoural phenotypes. J Neuroendocrinol 23: 1214-1221
29. Sanno N, Sugawara A, Teramoto A, Abe Y, Yen PM, Chin WW, Osamura RY 1997 Immunohistochemical expression of retinoid X receptor isoforms in human pituitaries and pituitary adenomas. Neuroendocrinology 65:299-306 (Pubitemid 27152087)
30. Bush ZM, Lopes MB, Hussaini IM, Jane Jr JA, Laws Jr ER, Vance ML 2010 Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. Pituitary 13:1-7
31. Pereira AM 2011 Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Curr Opin Endocrinol Diabetes Obes 18:264-268
32. Kurie JM 1999 The biologic basis of the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 11:497-502 (Pubitemid 29515895)
33. Jain S 2004 Topical tretinoin or adapalene in acne vulgaris: an overview. J Dermatolog Treat 15:200-207 (Pubitemid 39013671)
34. Arechalde A, Saurat JH 2000 Management of psoriasis: the position of retinoic acid. BioDrugs 13:327-333 (Pubitemid 30399445)
35. Fenaux P, Wang ZZ, Degos L 2007 Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 313:101-128 (Pubitemid 47400335)